Oncology — Pharmacokinetics Simulators

50 interactive PK simulators available for oncology drugs.

About Oncology Pharmacokinetics

Oncology pharmacokinetics encompasses the study of drug absorption, distribution, metabolism, and elimination of anti-cancer agents. Understanding PK properties is critical for optimizing dosing of chemotherapy, targeted therapies, immune checkpoint inhibitors, and antibody-drug conjugates to maximize efficacy while minimizing toxicity.

Small Molecule

Compare →

Ibrance (Palbociclib)

Oral• 1-CMT PopPK

HR+/HER2- metastatic breast cancer

Imatinib

Oral• PopPK

CML / GIST

Imbruvica (Ibrutinib)

Oral• 1-CMT PopPK

Chronic lymphocytic leukemia

Infigratinib

Oral• PopPK

Cholangiocarcinoma

Lynparza (Olaparib)

Oral• 1-CMT PopPK

BRCA-mutated ovarian cancer

Oncology Dose Selection Tool

Oral• PK/PD

Solid Tumors

Pomalyst (Pomalidomide)

Oral• 1-CMT PopPK

Multiple myeloma

Revlimid (Lenalidomide)

Oral• 1-CMT PopPK

Multiple myeloma

Tagrisso (Osimertinib)

Oral• 1-CMT PopPK

EGFR-mutated non-small cell lung cancer

Verzenio (Abemaciclib)

Oral• 1-CMT PopPK

HR+/HER2- metastatic breast cancer

Xtandi (Enzalutamide)

Oral• 1-CMT PopPK

Metastatic castration-resistant prostate cancer

mAb

Compare →

Darzalex (Daratumumab)

IV• 2-CMT PopPK

Multiple myeloma

Imfinzi (Durvalumab)

IV• 2-CMT PopPK

Non-small cell lung cancer

Keytruda (Pembrolizumab)

IV• 2-CMT PopPK

Melanoma and non-small cell lung cancer

Opdivo (Nivolumab)

IV• 2-CMT PopPK

Melanoma and non-small cell lung cancer

Perjeta (Pertuzumab)

IV• 2-CMT PopPK

HER2-positive breast cancer

T-cell Engager

IV• PK/PD

Hematologic Malignancies

Tecentriq (Atezolizumab)

IV• 2-CMT PopPK

Non-small cell lung cancer

Trastuzumab

IV• PopPK

HER2+ Breast Cancer

Trastuzumab

IV• PopPK

HER2+ Breast Cancer

Tumor Exposure Analysis

IV• PK/PD

Solid Tumors

Antibody-Drug Conjugate (ADC)

Compare →

ADCs

IV Infusion• Population PK

HER2-positive breast cancer, NSCLC, gastric/GEJ cancer

Dato

IV• Population PK

TROP2-positive metastatic breast cancer and other TROP2-expressing solid tumors

Datopotamab Deruxtecan (Datroway)

IV Infusion• Population PK (2-CMT ADC parallel linear+MM + 1-CMT Payload)

Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload

Enhertu

IV Infusion• Population PK (Sequential 2-CMT ADC + 1-CMT Payload)

HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC

PBPK-PD Topo1-Based ADC

Intravenous• PBPK-PD Model

Solid tumors (breast, lung, gastric, colorectal cancer)

PBPK-PD Topo1-Based ADC

Intravenous• PBPK-PD Model

Solid tumors (breast, lung, gastric, colorectal cancer)

PBPK-PD of ADCs

IV• PBPK-PD

Exposure and ILD risk assessment for trastuzumab deruxtecan and related ADC therapy

Sacituzumab Govitecan (Trodelvy)

IV Infusion• Population PK (Triple-analyte: ADC + SN-38 payload + total antibody)

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload

Antimetabolite

Compare →

5-Fluorouracil

IV• popPK

Cancer chemotherapy

Methotrexate High-Dose

IV• popPK

Cancer/RA

PARP Inhibitor

Compare →

rucaparib ok

Oral• PopPK (2-compartment)

Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC)

rucaparib

IV• Population PK/PD

PARP-targeted therapy in advanced solid tumors including ovarian cancer

PROTAC

Compare →

BTK Degrader

Oral• PopPK

B-cell Malignancies

BTK Targeted Degrader

Oral• PK/PD

B-cell Malignancies

ADC

ADC Effector Function

IV• PK/PD

Solid Tumors

Anthracycline

Doxorubicin

IV• popPK

Cancer chemotherapy

Anti-HER2 Monoclonal Antibody

Trastuzumab (Herceptin) PBPK-TMDD

IV• Minimal PBPK-TMDD

HER2-positive breast cancer

Antibody-Drug Conjugate

PBPK-PD Topo1-Based ADC

IV• PBPK-PD

Solid tumors (HER2-positive and Trop-2-positive cancers)

Fluoropyrimidine / Oral Prodrug

Capecitabine and 5-FU

Oral• Sequential metabolite PopPK (capecitabine to 5'-DFCR to 5'-DFUR to 5-FU)

Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma

Fluoropyrimidine antimetabolite

5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses

IV infusion• PK/PD model with 2-compartment Michaelis-Menten PK and Friberg myelosuppression PD

Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens

Monoclonal Antibody (Anti-HER2)

TMDD

IV Infusion• Minimal PBPK-TMDD with Target Shedding

HER2-positive Breast Cancer

Monoclonal Antibody (anti-PD-1)

Serplulimab (HLX10) Population

IV Infusion• Two-Compartment with Time-Dependent Clearance

Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Monoclonal antibody

Pertuzumab

IV infusion• 2-compartment PopPK

HER2-positive solid tumors

Multikinase Inhibitor (TKI)

lenvatinib_Gupta_26879594

Oral• Population PK

Advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer

PARP inhibitor

Ruc

Oral• Semi-mechanistic PK/PD

BRCA-mutant and HRD+ breast cancer

PD-1 inhibitor

Keytruda

IV• popPK

Cancer immunotherapy

Platinum

Cisplatin

IV• popPK

Cancer chemotherapy

Taxane

Paclitaxel

IV• popPK

Cancer chemotherapy

Taxane / Microtubule stabilizer

Docetaxel

IV infusion• 3-compartment PopPK with covariate effects

Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer

Disclaimer: These simulators are for educational and research purposes only. Pharmacokinetic models are based on published literature and may not reflect individual patient variability. Not intended for clinical decision-making. Always consult prescribing information and clinical guidelines.

← All AreasAll SimulatorsCompare Drugs →